Year: 2022
BERGENBIO ANNOUNCES LAUNCH OF BUSINESS STRATEGY FOCUSED ON NSCLC AND COVID-19
May 4, 2022
BerGenBio to focus on two key opportunities for its lead compound bemcentinibStrategic focus anchored in…
Read MoreBERGENBIO ANNOUNCES COMPLETE DATA ANALYSIS OF ACCORD2 PHASE II BEMCENTINIB STUDY IN HOSPITALIZED COVID-19 PATIENTS – PRIMARY EFFICACY ENDPOINT MET
April 26, 2022
Complete data analysis confirms that the primary endpoint of improved clinical response and key secondary…
Read MoreBERGENBIO PRESENTS BEMCENTINIB COVID-19 CLINICAL TRIAL DATA AT ECCMID 2022
April 25, 2022
Bergen, Norway, 25 April 2022 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel,…
Read More
BERGENBIO STRENGTHENS ITS LEADERSHIP TEAM WITH APPOINTMENT OF CRISTINA OLIVA AS CHIEF MEDICAL OFFICER
April 11, 2022
Bergen, Norway, 11 April 2022 - BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…
Read MoreBERGENBIO ASA: NOTICE OF ANNUAL GENERAL MEETING
April 7, 2022
Bergen, Norway – 7 April 2022: BerGenBio ASA (OSE:BGBIO) will be holding its Annual General…
Read MoreBERGENBIO ASA: BOARD APPROVAL OF 2021 ANNUAL FINANCIAL STATEMENT AND ANNUAL REPORT 2021
April 7, 2022
Bergen, Norway – 7 April 2022 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing…
Read More
